The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca2 + signalling in steatotic hepatocytes

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1863, Issue 9, 2016, Pages 2135-2146

  Ali, Eunüs S ^a   Hua, Jin ^a   Wilson, Claire H ^b   Tallis, George A ^c   Zhou, Fiona H ^d   Rychkov, Grigori Y ^d   Barritt, Greg J ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Exendin 4; GLP 1; Intracellular Ca2 +; Liver; Steatosis; Store operated Ca2 + entry; Cyclic AMP

Indexed keywords

AMIODARONE; BUCLADESINE; CALCIUM ION; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL; CYCLIC AMP; DIACYLGLYCEROL; EXENDIN 4; FURA 2; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; GLYCOGEN; PALMITIC ACID; PHENYLEPHRINE; PROTEIN KINASE C; CALCIUM; HORMONE; PEPTIDE; VENOM;

ANIMAL CELL; ARTICLE; CALCIUM SIGNALING; CELL ISOLATION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; FATTY LIVER; HOMEOSTASIS; LIPID STORAGE; LIPOLYSIS; LIVER CELL; NONHUMAN; PATCH CLAMP TECHNIQUE; PRIORITY JOURNAL; RAT; STEATOTIC HEPATOCYTE; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; INTRACELLULAR SPACE; METABOLISM; PATHOLOGY; ZUCKER RAT;

ANIMALS; BUCLADESINE; CALCIUM; CALCIUM SIGNALING; CYCLIC AMP; FATTY LIVER; GLUCAGON-LIKE PEPTIDE 1; HEPATOCYTES; HORMONES; INTRACELLULAR SPACE; PALMITIC ACID; PEPTIDES; RATS, ZUCKER; VENOMS;

EID: 84989934412     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2016.05.006     Document Type: Article

References (68)

1. [1] Birkenfeld, A.L., Shulman, G.I., Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 59 (2014), 713–723.
2. [2] Williams, K.H., Shackel, N.A., Gorrell, M.D., McLennan, S.V., Twigg, S.M., Diabetes and nonalcoholic fatty liver disease: a pathogenic duo. Endocr. Rev. 34 (2013), 84–129.
3. [3] Samson, S.L., Bajaj, M., Potential of incretin-based therapies for non-alcoholic fatty liver disease. J. Diabetes Complicat. 27 (2013), 401–406.
4. [4] Bishara, N.B., Ding, H., Glucose enhances expression of TRPC1 and calcium entry in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 298 (2010), H171–H178.
5. [5] Campbell, J.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17 (2013), 819–837.
6. [6] Liu, Y., Wei, R., Hong, T.P., Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease. World J. Gastroenterol. 20 (2014), 9090–9097.
7. [7] Arruda, A.P., Hotamisligil, G.S., Calcium homeostasis and organelle function in the pathogenesis of obesity and diabetes. Cell Metab. 22 (2015), 381–397.
8. [8] Perry, R.J., Samuel, V.T., Petersen, K.F., Shulman, G.I., The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510 (2014), 84–91.
9. [9] Bartlett, P.J., Gaspers, L.D., Pierobon, N., Thomas, A.P., Calcium-dependent regulation of glucose homeostasis in the liver. Cell Calcium 55 (2014), 306–316.
10. [10] Cantley, J.L., Yoshimura, T., Camporez, J.P., Zhang, D., Jornayvaz, F.R., Kumashiro, N., Guebre-Egziabher, F., Jurczak, M.J., Kahn, M., Guigni, B.A., Serr, J., Hankin, J., Murphy, R.C., Cline, G.W., Bhanot, S., Manchem, V.P., Brown, J.M., Samuel, V.T., Shulman, G.I., CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 1869–1874.
11. [11] Fu, S., Yang, L., Li, P., Hofmann, O., Dicker, L., Hide, W., Lin, X., Watkins, S.M., Ivanov, A.R., Hotamisligil, G.S., Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature 473 (2011), 528–531.
12. [12] Blaslov, K., Bulum, T., Zibar, K., Duvnjak, L., Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J. Gastroenterol. 20 (2014), 7356–7365.
13. [13] Marathe, C.S., Rayner, C.K., Jones, K.L., Horowitz, M., Glucagon-like peptides 1 and 2 in health and disease: a review. Peptides 44 (2013), 75–86.
14. [14] Arch, J.R., Thermogenesis and related metabolic targets in anti-diabetic therapy. Handb. Exp. Pharmacol., 2011, 201–255.
15. [15] Wang, X.C., Gusdon, A.M., Liu, H., Qu, S., Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J. Gastroenterol. 20 (2014), 14821–14830.
16. [16] Lee, J., Hong, S.W., Chae, S.W., Kim, D.H., Choi, J.H., Bae, J.C., Park, S.E., Rhee, E.J., Park, C.Y., Oh, K.W., Park, S.W., Kim, S.W., Lee, W.Y., Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS One, 7, 2012, e31394.
17. 2 + through a protein kinase C-dependent mechanism. Biochem. J. 466 (2015), 379–390.
18. 2 + -permeable channels in the hepatocyte plasma membrane and their roles in hepatocyte physiology. Biochim. Biophys. Acta 1783 (2008), 651–672.
19. 2 + channels and Stromal Interaction Molecule 1 (STIM1) are targets for the actions of bile acids on liver cells. Biochim. Biophys. Acta, Mol. Cell Res. 1783 (2008), 874–885.
20. - channels in rat hepatocytes. J. Physiol. Lond. 573 (2006), 611–625.
21. [21] Greenspan, P., Mayer, E.P., Fowler, S.D., Nile red: a selective fluorescent stain for intracellular lipid droplets. J. Cell Biol. 100 (1985), 965–973.
22. [22] Kheradpezhouh, E., Ma, L., Morphett, A., Barritt, G.J., Rychkov, G.Y., TRPM2 channels mediate acetaminophen-induced liver damage. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 3176–3181.
23. 2 + channel activation in liver cells: evidence from studies using TRPV1 and taurodeoxycholic acid. Biochem. J. 418 (2009), 553–566.
24. 2 + indicators with greatly improved fluorescence properties. J. Biol. Chem. 260 (1985), 3440–3450.
25. [25] Pradelles, P., Grassi, J., Chabardes, D., Guiso, N., Enzyme immunoassays of adenosine cyclic 3',5'-monophosphate and guanosine cyclic 3',5'-monophosphate using acetylcholinesterase. Anal. Chem. 61 (1989), 447–453.
26. [26] Ding, X., Saxena, N.K., Lin, S., Gupta, N.A., Anania, F.A., Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43 (2006), 173–181.
27. [27] Dhanesha, N., Joharapurkar, A., Shah, G., Dhote, V., Kshirsagar, S., Bahekar, R., Jain, M., Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect. Pharmacol. Rep. 64 (2012), 140–149.
28. [28] Dhanesha, N., Joharapurkar, A., Shah, G., Dhote, V., Kshirsagar, S., Bahekar, R., Jain, M., Exendin-4 ameliorates diabetic symptoms through activation of glucokinase. J. Diabetes 4 (2012), 369–377.
29. [29] Dalvi, P.S., Nazarians-Armavil, A., Purser, M.J., Belsham, D.D., Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding-associated neuropeptides in hypothalamic neurons in vivo and in vitro. Endocrinology 153 (2012), 2208–2222.
30. [30] Park, C.W., Kim, H.W., Ko, S.H., Lim, J.H., Ryu, G.R., Chung, H.W., Han, S.W., Shin, S.J., Bang, B.K., Breyer, M.D., Chang, Y.S., Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J. Am. Soc. Nephrol. 18 (2007), 1227–1238.
31. [31] Ji, H., Shen, X.D., Zhang, Y., Gao, F., Huang, C.Y., Chang, W.W., Lee, C., Ke, B., Busuttil, R.W., Kupiec-Weglinski, J.W., Activation of cyclic adenosine monophosphate-dependent protein kinase a signaling prevents liver ischemia/reperfusion injury in mice. Liver Transpl. 18 (2012), 659–670.
32. [32] Ding, X., Staudinger, J.L., Induction of drug metabolism by forskolin: the role of the pregnane X receptor and the protein kinase a signal transduction pathway. J. Pharmacol. Exp. Ther. 312 (2005), 849–856.
33. [33] Dighe, R.R., Rojas, F.J., Birnbaumer, L., Garber, A.J., Glucagon-stimulable adenylyl cyclase in rat liver. Effects of chronic uremia and intermittent glucagon administration. J. Clin. Invest. 73 (1984), 1004–1012.
34. [34] Harano, Y., Kashiwagi, A., Kojima, H., Suzuki, M., Hashimoto, T., Shigeta, Y., Phosphorylation of carnitine palmitoyltransferase and activation by glucagon in isolated rat hepatocytes. FEBS Lett. 188 (1985), 267–272.
35. [35] Wang, Y., Li, G., Goode, J., Paz, J.C., Ouyang, K., Screaton, R., Fischer, W.H., Chen, J., Tabas, I., Montminy, M., Inositol-1,4,5-trisphosphate receptor regulates hepatic gluconeogenesis in fasting and diabetes. Nature 485 (2012), 128–132.
36. [36] Exton, J.H., Mechanisms of hormonal regulation of hepatic glucose metabolism. Diabetes Metab. Rev. 3 (1987), 163–183.
37. [37] Exton, J.H., Blackmore, P.F., El-Refai, M.F., Dehaye, J.P., Strickland, W.G., Cherrington, A.D., Chan, T.M., Assimacopoulos-Jeannet, F.D., Chrisman, T.D., Mechanisms of hormonal regulation of liver metabolism. Adv. Cyclic Nucleotide Res. 14 (1981), 491–505.
38. [38] Beebe, S.J., Koch, S.R., Chu, D.T., Corbin, J.D., Granner, D.K., Regulation of phosphoenolpyruvate carboxykinase gene transcription in H4IIE hepatoma cells: evidence for a primary role of the catalytic subunit of 3',5'-cyclic adenosine monophosphate-dependent protein kinase. Mol. Endocrinol. 1 (1987), 639–647.
39. [39] Debeer, L.J., Beynen, A.C., Mannaerts, G.P., Geelen, M.J., Lipolysis of hepatic triacylglycerol stores. FEBS Lett. 140 (1982), 159–164.
40. [40] Gupta, N.A., Kolachala, V.L., Jiang, R., Abramowsky, C., Romero, R., Fifadara, N., Anania, F., Knechtle, S., Kirk, A., The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis. Am. J. Pathol. 181 (2012), 1693–1701.
41. [41] Gupta, N.A., Mells, J., Dunham, R.M., Grakoui, A., Handy, J., Saxena, N.K., Anania, F.A., Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51 (2010), 1584–1592.
42. [42] Sharma, S., Mells, J.E., Fu, P.P., Saxena, N.K., Anania, F.A., GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One, 6, 2011, e25269.
43. 2 + influx and IL-2 production in T lymphocytes. J. Immunol. 170 (2003), 4441–4449.
44. [44] Amaya, M.J., Nathanson, M.H., Calcium signaling in the liver. Compr. Physiol. 3 (2013), 515–539.
45. [45] Pilkis, S.J., Granner, D.K., Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu. Rev. Physiol. 54 (1992), 885–909.
46. [46] Huhn, W., Schulze, H.P., Dargel, R., Effect of glucagon, phenylephrine, and isoproterenol on glycogenolysis and glucose release from fetal rat hepatocytes in suspension. Biol. Neonate 44 (1983), 153–157.
47. [47] Jornayvaz, F.R., Shulman, G.I., Diacylglycerol activation of protein kinase Cepsilon and hepatic insulin resistance. Cell Metab. 15 (2012), 574–584.
48. [48] Flock, G., Baggio, L.L., Longuet, C., Drucker, D.J., Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56 (2007), 3006–3013.
49. [49] Svegliati-Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., Garelli, P., Casini, A., Manco, M., Mingrone, G., Risaliti, A., Frega, G.N., Benedetti, A., Gastaldelli, A., Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 31 (2011), 1285–1297.
50. [50] Jornayvaz, F.R., Shulman, G.I., Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metab. 15 (2012), 574–584.
51. [51] Tomas, E., Stanojevic, V., Habener, J.F., GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul. Pept. 167 (2011), 177–184.
52. [52] Martinez-Lopez, N., Singh, R., Autophagy and lipid droplets in the liver. Annu. Rev. Nutr. 35 (2015), 215–237.
53. [53] Mashek, D.G., Khan, S.A., Sathyanarayan, A., Ploeger, J.M., Franklin, M.P., Hepatic lipid droplet biology: getting to the root of fatty liver. Hepatology 62 (2015), 964–967.
54. [54] Quiroga, A.D., Lehner, R., Liver triacylglycerol lipases. Biochim. Biophys. Acta 1821 (2012), 762–769.
55. [55] Amrutkar, M., Cansby, E., Nunez-Duran, E., Pirazzi, C., Stahlman, M., Stenfeldt, E., Smith, U., Boren, J., Mahlapuu, M., Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH. FASEB J. 29 (2015), 1564–1576.
56. [56] Pawella, L.M., Hashani, M., Eiteneuer, E., Renner, M., Bartenschlager, R., Schirmacher, P., Straub, B.K., Perilipin discerns chronic from acute hepatocellular steatosis. J. Hepatol. 60 (2014), 633–642.
57. [57] Walther, T.C., Farese, R.V. Jr., Lipid droplets and cellular lipid metabolism. Annu. Rev. Biochem. 81 (2012), 687–714.
58. 2 + mobilization under the control of glucagon-like peptide-1 in mouse pancreatic beta-cells. Am. J. Physiol. Cell Physiol. 310 (2016), C337–C347.
59. 2 +-ATPase 2b is a major regulator of endoplasmic reticulum stress and glucose homeostasis in obesity. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 19320–19325.
60. [60] Shim, A.H., Tirado-Lee, L., Prakriya, M., Structural and functional mechanisms of CRAC channel regulation. J. Mol. Biol. 427 (2015), 77–93.
61. [61] Taher, J., Baker, C.L., Cuizon, C., Masoudpour, H., Zhang, R., Farr, S., Naples, M., Bourdon, C., Pausova, Z., Adeli, K., GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance. Mol. Metab. 3 (2014), 823–833.
62. [62] Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., Halpern, Z., Barzilai, N., Oren, R., Fishman, S., Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J. Hepatol. 54 (2011), 1214–1223.
63. [63] Baumbach, J., Hummel, P., Bickmeyer, I., Kowalczyk, K.M., Frank, M., Knorr, K., Hildebrandt, A., Riedel, D., Jackle, H., Kuhnlein, R.P., A Drosophila in vivo screen identifies store-operated calcium entry as a key regulator of adiposity. Cell Metab. 19 (2014), 331–343.
64. [64] Brasaemle, D.L., Wolins, N.E., Packaging of fat: an evolving model of lipid droplet assembly and expansion. J. Biol. Chem. 287 (2012), 2273–2279.
65. [65] Mekahli, D., Bultynck, G., Parys, J.B., De Smedt, H., Missiaen, L., Endoplasmic-reticulum calcium depletion and disease. Cold Spring Harb. Perspect. Biol., 3, 2011.
66. [66] Lee, J., Hong, S.W., Park, S.E., Rhee, E.J., Park, C.Y., Oh, K.W., Park, S.W., Lee, W.Y., Exendin-4 regulates lipid metabolism and fibroblast growth factor 21 in hepatic steatosis. Metabolism 63 (2014), 1041–1048.
67. [67] Francini, F., Massa, M.L., Polo, M.P., Villagarcia, H., Castro, M.C., Gagliardino, J.J., Control of liver glucokinase activity: a potential new target for incretin hormones?. Peptides 74 (2015), 57–63.
68. [68] Kim, S., Jung, J., Kim, H., Heo, R.W., Yi, C.O., Lee, J.E., Jeon, B.T., Kim, W.H., Hahm, J.R., Roh, G.S., Exendin-4 improves nonalcoholic fatty liver disease by regulating glucose transporter 4 expression in ob/ob mice. Korean J. Physiol. Pharmacol. 18 (2014), 333–339.